Traditional Unani Medicine Decoction May Help in Managing Bronchial Asthma

EFFECTS OF POLYHERBAL UNANI FORMULATION JOSHANDA (DECOCTION), IN THE TREATMENT OF DIQ AL-NAFAS (BRONCHIAL ASTHMA), NON RANDOMIZED, A SINGLE –ARM, PRE AND POST INTERVENTIONAL STUDY WITHOUT CONTROL. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/09/074373

Enrollment

Registered

2024-09-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J989- Respiratory disorder, unspecified

Interventions

Intervention1: POLYHERBAL UNANI FORMULATION JOSHANDA ,DECOCTION OF 1.Baranjasif [Achillea mellifolium Linn] 2. Hasha [Thymus serpyllum Linn] 3.Zarawand Madahraj [Aristocolia rotunda

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either gender in age group of 18-60yrs 2.Patients of Bronchial Asthma for at least 6 months presenting with at least are the following Symtoms wheeze Shortness Of Breath Chest tightness & cough that vary overtime intensity Expiratory airflow limitation as suggested by a decreased FEV1=80 3.Patient with Asthma Control Test = 19 4. Non smoker

Exclusion criteria

Exclusion criteria: 1. Patients below 18yrs. and above 60 yrs. 2. Patient with Upper Respiratory Tract infection, chronic obstructive airway disease (COAD) including chronic bronchitis and emphysema. 3. Patients with Comorbidities, Diabetes, Hepatic Disorders, Renal insufficiency, Hypertension and Heart diseases. 4. Patient with other respiratory tract infection, pulmonary Tuberculosis, occupational lung diseases and Malignancy. 5. Patient with Cognitive impairment. 6. Patient with regular use of oral or systemic corticosteroids for condition other than Asthma. 7.FEV1/FVC ratio = 80 8. History of addiction (Smoking, alcohol, drugs) 9. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Improvement in ACQ score, Improvement in signs and symptoms of DIQ AL - Nafas (Bronchial Asthma)Timepoint: 28 DAYS	—

Secondary

Measure	Time frame
Improvement in Spirometer parameters Hematological and biochemical assessmentTimepoint: 28 DAYS	—

Countries

India

Contacts

Public ContactDR A KHALEEL AHMED MD

GOVERNMENT UNANI MEDICAL COLLEGE

ahmedkhaleel869@gmail.com7358321528

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026